P-Monofer-CHF-02 — Ferric Derisomaltose
Iron-Deficient Chronic Heart Failure
Sponsor: Pharmacosmos · P-Monofer-CHF-02
About this study
Phase 3 evaluation of intravenous ferric derisomaltose (Monofer) in patients with chronic heart failure and iron deficiency.
To evaluate whether intravenous iron replacement improves cardiovascular outcomes and quality of life in adults with chronic heart failure and iron deficiency.
Study details
- Sponsor
- Pharmacosmos
- Protocol
- P-Monofer-CHF-02
- Phase
- Phase 3
- Indication
- Iron-Deficient Chronic Heart Failure
- Status
- Currently Recruiting
High-level eligibility
- Adults with HFrEF or HFpEF
- Confirmed iron deficiency (TSAT <20% or ferritin criteria)
- Stable on guideline-directed therapy
Eligibility above is a summary. Final qualification is determined by the study protocol and a screening visit at amavita Heart and Vascular Health®.
I'm a sponsor / CRO →
Discuss enrollment, capacity, and operational fit.
I might be eligible — call (786) 703-5941 →
Free, no-obligation pre-screen in English / Spanish / Haitian Creole.
Participation in any clinical trial is voluntary and requires written informed consent reviewed by an Institutional Review Board (IRB) before any study procedure. You may withdraw at any time. Website content is informational and is not a substitute for medical advice from a licensed clinician.